Rhinomed Limited
RHNMF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $7,472 | $9,105 | $3,895 | $3,565 |
| % Growth | -17.9% | 133.8% | 9.2% | – |
| Cost of Goods Sold | $7,663 | $2,899 | $1,142 | $1,450 |
| Gross Profit | -$190 | $6,206 | $2,753 | $2,115 |
| % Margin | -2.5% | 68.2% | 70.7% | 59.3% |
| R&D Expenses | $1,161 | $1,716 | $732 | $180 |
| G&A Expenses | $1,308 | $5,096 | $6,909 | $6,022 |
| SG&A Expenses | $11,813 | $9,859 | $10,267 | $8,612 |
| Sales & Mktg Exp. | $5,615 | $4,763 | $3,358 | $2,590 |
| Other Operating Expenses | -$3,176 | $383 | $907 | $1,409 |
| Operating Expenses | $9,798 | $11,958 | $11,906 | $10,200 |
| Operating Income | -$9,410 | -$6,026 | -$8,850 | -$8,085 |
| % Margin | -125.9% | -66.2% | -227.2% | -226.8% |
| Other Income/Exp. Net | -$1,497 | $745 | $213 | $0 |
| Pre-Tax Income | -$11,449 | -$5,280 | -$8,638 | -$7,265 |
| Tax Expense | -$541 | $1 | $1 | $1 |
| Net Income | -$10,908 | -$5,281 | -$8,639 | -$7,266 |
| % Margin | -146% | -58% | -221.8% | -203.8% |
| EPS | -0.038 | -0.02 | -0.034 | -0.044 |
| % Growth | -89.1% | 40.2% | 23.2% | – |
| EPS Diluted | -0.038 | -0.02 | -0.034 | -0.044 |
| Weighted Avg Shares Out | 285,720 | 261,656 | 255,529 | 165,135 |
| Weighted Avg Shares Out Dil | 285,720 | 261,656 | 255,529 | 165,135 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $29 | $14 |
| Interest Expense | $313 | $44 | $41 | $0 |
| Depreciation & Amortization | -$892 | $699 | $592 | $596 |
| EBITDA | -$9,096 | -$4,536 | -$8,005 | -$6,677 |
| % Margin | -121.7% | -49.8% | -205.5% | -187.3% |